SAN DIEGO, March 21 /PRNewswire/ -- EDC Biosystems, Inc. and Aurora Discovery, Inc. today announced an agreement to co-market EDC Biosystems’ acoustic liquid-handling instrumentation and Aurora Discovery’s ChemLib(TM) microplates aimed at significantly increasing the productivity and performance of drug discovery laboratories. EDC Biosystems’ EnRoute HTS 02 instrument provides researchers with a non-contact alternative for liquid-handling operations in low volume microplates. When used with ChemLib 1536-well or 3456-well microplates, the EnRoute workstation is a significant advancement for key activities in drug discovery -- including compound reformatting, hit picking, and compound library auditing.
“Researchers have found superior performance when using cyclo-olefin polymer microplates on our instrumentation compared to conventional polypropylene and polystyrene plates. This partnership with Aurora Discovery enables EDC Biosystems to leverage Aurora Discovery’s cyclo-olefin ChemLib plates and offer a fundamental advancement to pharmaceutical researchers -- substantial results in low volume assays,” said Roger Williams, EDC Biosystems President and CEO.
“Acoustic dispensing is a promising technology that augments Aurora Discovery’s current platforms which provide miniaturization solutions for discovery sciences,” said Peter Coassin, Aurora Discovery’s President and CTO. “This technology partnership with EDC Biosystems addresses one of the most challenging aspects of modern drug discovery -- namely, the rapid turn around on hit picking and dose response profiling of compounds identified in an ultra-high throughput screen.” Aurora Discovery has combined state of the art microplate technology with precise, non-contact dispensers, now including the EnRoute HTS 02, to simplify the miniaturization of drug discovery assays and accelerate pharmaceutical research.
About EDC Biosystems
EDC Biosystems is a provider of research and development instruments and services for the combinatorial materials science and drug discovery market. The Company specializes in solutions for managing vast libraries of liquid compounds, which demand precise and rapid handling. EDC Biosystems builds close, collaborative relationships with biotechnology, and industrial partners. Additionally, EDC Biosystems is pursuing joint development partnerships that further our technology development. EDC Biosystems integrates global research with extensive engineering talent and more than 25 years of experience in building real production process environments. For more information, visit the EDC Biosystems web site at http://www.edcbiosystems.com/.
About Aurora Discovery
Aurora Discovery, Inc. is a leading provider of miniaturization solutions for discovery sciences. The company designs, manufactures, markets, and supports instrumentation and consumables for pharmaceutical research, particularly drug discovery and chemical genomics. Aurora Discovery’s products accelerate drug discovery and help its pharmaceutical customers to select novel chemical entities quicker and ultimately, develop new medicines and therapies more rapidly and cost-effectively. Located in San Diego, California, the company provides high value solutions to the pharmaceutical research challenge through high-density microplate formats, precision non-contact dispensers for chemical compounds and biological reagents, multi-wavelength fluorescence detectors, and systems integration. For more information, visit Aurora Discovery on its website at http://www.auroradiscovery.com/.
Aurora Discovery, Inc.
CONTACT: Roger O. Williams, CEO of EDC Biosystems, Inc.,+1-408-273-2299, info@edcbiosystems.com; or Chris Biagioli, Marketing Managerof Aurora Discovery, Inc., +1-858-334-4508, marcom@auroradiscovery.com
